DDrare: Database of Drug Development for Rare Diseases

144. レノックス・ガストー症候群
［臨床試験数：80，薬物数：63（DrugBank：11），標的遺伝子数：49，標的パスウェイ数：59］

Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Any other approved Antiepileptic Drug; CANNABIDIOL; CBD; CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA.; CLOBAZAM; Cannabidiol; Cannabidiol (CBD); Cannabidiol Oral Solution; Carisbamate; Clobazam; Clobazam High Dose; Clobazam Low Dose; Clobazam Medium Dose; Clobazam PhEur; Clobazam Pheur; Clobazam Tablets; Clobazam Tablets 10mg; Clobazam Tablets 20mg; Clobazam Tablets 5mg; E2007; E2080; EZOGABINE (US ONLY); EZOGABINE (US only); Ezogabine; Ezogabine/retigabine; FENFLURAMINE HYDROCHLORIDE; Fenfluramine; Fenfluramine HCl, DL-Fenfluramine, (±)-Fenfluramine; Fenfluramine hydrochloride (colorless); Fycompa; GW582892; GWP42003-P; GWP42003-P 20 mg/kg/day Dose; Inovelon; Investigators Choice of Approved AED; Investigators choice of approved AEDs; Lamictal; Lamotrigine; Melatonin; PERAMPANEL; Perampanel; Placebo; Potiga; Procedure: 12-Lead ECG; RETIGABINE; RETIGABINE/EZOGABINE; RUFINAMIDE; Retigabine; Retigabine/Ezogabine; Retigabine/ezogabine; Rufinamide; Rufinamide (E2080); Rufinamide oral suspension; Sodio valproato; TAK-935; Topimarate; Topimarato; Topiramate; Turmeric; ZX008; ZX008 (Fenfluramine Hydrochloride); ZX008 0.2 and 0.8 mg/kg/day; ZX008 0.2 or 0.8 mg/kg/day

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01370486 (ClinicalTrials.gov)	August 2011	8/6/2011	Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects	Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects	Lennox-Gastaut Syndrome	Drug: melatonin;Drug: placebo	Institution de Lavigny	NULL	Not yet recruiting	18 Years	55 Years	Both	6	Phase 4	Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01370486
(ClinicalTrials.gov)

August 2011

8/6/2011

Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects

Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects

Lennox-Gastaut Syndrome

Drug: melatonin;Drug: placebo

Institution de Lavigny

NULL

Not yet recruiting

18 Years

55 Years

Both

Phase 4

Switzerland